The differential drug sensitivities associated with CTH and MAP1LC3B highlight their potential as biomarkers for personalized treatment strategies, offering a promising avenue for improving therapeutic outcomes in GC patients. The gene discussed is MAP1LC3B; the disease is gastric cancer.